ACIP Update and Vaccine Safety

Amanda Timmons
Oregon Immunization Program

ACIP Update

Advisory Committee on Immunization Practices (ACIP)

Group of medical and public health experts
Writes routine immunization recommendations for the U.S.
June 2019 Meeting

- HPV
- Pneumococcal
- Combinations
- Zoster
- Pertussis
- Influenza
- Hepatitis A
- Meningococcal
- Dengue

HPV Vaccines

HPV Vaccine

- Catch-up vaccination for males and females through age 26 years.
- Clinicians may choose to vaccinate adults between 27 and 45 years.
Pneumococcal Vaccine

- PCV13 recommended for adults 65 years and older since 2014
- Meant to be a short-term intervention due to herd immunity
Policy Options

- Continue recommending PCV13 for all adults 65 years and older.
- Recommend shared clinical decision making for healthy adults 65 years and older.
- Stop recommending PCV13 for all adults 65 years and older.

Pneumococcal Vaccine Vote

ACIP recommends PCV13 based on shared clinical decision making for adults 65 years or older who do not have an immunocompromising condition and who have not previously received PCV13. All adults 65 years or older should receive a dose of PPSV23.
Pediatric hexavalent vaccine

- Licensed on December 21, 2018 – not commercially available until 2021.
- Contains diphtheria, tetanus, pertussis, polio, *Haemophilus influenzae* type b, and hepatitis B.
- Abbreviated DTaP-IPV-Hib-HepB
- Given at 2, 4, 6 months
- Will be available through VFC

Pertussis vaccines

Pertussis vaccine

- Tdap claims are 11.7x those of Td
- Difficult to determine which adults need Tdap
- Cumbersome to stock both vaccines

ACIP recommends that either Tdap or Td can be used:

- For boosters every 10 years
- For wound prophylaxis
- For catch-up vaccination
2019-20 Influenza Updated
Recommendations

- **Timing**
  - For those requiring only one dose, vaccination in July and August is likely to result in suboptimal immunity before the end of flu season, especially in older adults.

- **Limited Supply**
  - Health care workers should be among the groups considered for prioritized receipt of influenza vaccines when vaccine supply is limited.

- **Unvaccinated 8-year-olds**
  - Unvaccinated 8-year-olds who turn 9 during flu season should still receive 2 flu doses.

- **Adjuvanted vaccines**
  - Consideration should be given to avoiding giving two vaccines with novel adjuvants at the same time.
2019-20 Inactivated Influenza Vaccine

- 0.25 mL 6M to 3Y
- 0.5 mL 3Y+
- 0.5 mL 4Y+
- 0.5 mL 6Y+
- 0.5 mL 65Y+
- 0.5 mL 6M+

2019-20 Live Influenza Vaccine

- 0.2 mL 2Y to 4Y

Hepatitis A Vaccines
Hepatitis A vaccine

- 1999: Routine vaccination for all 2-year-olds in Oregon. Catch-up immunization for children under age 18 years.
- 2006: Routine vaccination for all U.S. children at 1-year of age.
- 2008: Oregon school requirement for children’s facilities and kindergarten entry. Additional grades added every year.

Hepatitis A updates

- All unvaccinated children under age 18 years should receive catch-up vaccination with hepatitis A.
- All persons with HIV over age 1 year should be vaccinated.

Meningococcal Vaccines
Meningococcal B boosters

• Necessary for people ≥ 10 years at high-risk
  – Asplenia
  – Complement deficiency
  – Complement inhibitor use
  – Microbiologist
  – Outbreaks

• Booster dose
  – 1 year after completion of the series
  – Every 2-3 years thereafter, as long as risk remains
  – May consider booster 6 months after completion in an outbreak

Vaccine Safety

Vaccine Adverse Events Reporting System (VAERS)

Vaccine Safety Datalink (VSD)

Clinical Immunization Safety Assessment (CISA)
Zoster Vaccine Safety

- VAERS
- Rapid Cycle Analysis (RCA) through Vaccine Safety Datalink
- Medicare data

Post-licensure RZV Monitoring

- No disproportional reporting to VAERS
- RCA signals for Bell’s palsy and Guillain-Barre Syndrome (GBS)
- Elevated rate ratio for GBS in Medicare claims data
Post-licensure RZV Monitoring

• Safety consistent with pre-licensure clinical trial data
• Medicare chart reviews are pending
• CDC will continue to monitor for GBS and Bell’s palsy
• Continued vigilance for RZV safety concerns